Shanghai Henlius Biotech, Inc. Class H had a revenue of 1.37B in the quarter ending Jun 30, 2024, with 0.00%. This bring the company's revenue in the last twelve months to 5.64B, Decreased 2.23%. In the fiscal year ending Dec 31, 2023, Shanghai Henlius Biotech, Inc. Class H had annual revenue of 5.39B with 67.82% growth.